Persijn G G, D'Amaro J
Scand J Urol Nephrol Suppl. 1985;92:91-3.
Since 1981, more and more transplant centres collaborating within the Eurotransplant Organization started to use Cyclosporin-A (CsA) as part of their immunosuppressive protocols. Although these protocols differ from centre to centre it was felt important to study the clinical significance of CsA on renal allograft survival, especially with regard to other relevant but more constant factors such as HLA-A, -B and -DR matching, pretransplant blood transfusions, ischemia times, etc. This study encompasses 3150 transfused kidney transplant recipients of whom 765 have received CsA. Analysis shows that the group of CsA treated patients had a significantly better graft survival as compared to the non-CsA treated patients i.e., 71% versus 62% at 2 years respectively. The best kidney graft survival was obtained in the HLA-DR well matched donor-recipients combinations even when CsA was used (79% at 2 years). A significant adverse effect of prolonged cold ischemia times was observed when CsA was administered.
自1981年以来，越来越多在欧洲移植组织内合作的移植中心开始将环孢素A（CsA）用作其免疫抑制方案的一部分。尽管这些方案因中心而异，但人们认为研究CsA对肾移植存活的临床意义很重要，特别是相对于其他相关但更恒定的因素，如HLA - A、- B和 - DR配型、移植前输血、缺血时间等。本研究涵盖了3150例接受输血的肾移植受者，其中765例接受了CsA治疗。分析表明，与未接受CsA治疗的患者相比，接受CsA治疗的患者组移植存活率显著更高，即2年时分别为71%和62%。即使使用了CsA，在HLA - DR配型良好的供体 - 受体组合中获得了最佳的肾移植存活率（2年时为79%）。当使用CsA时，观察到延长冷缺血时间有显著的不良影响。
